A practical reference on Photo-oxidation: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-17 and is reviewed periodically as new material appears.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Peptide backbone with a fatty diacid chain |
| Molecular weight | About 4813 Da | Calculated from the formula |
| Receptor targets | GIP and GLP-1 receptors | Dual agonist activity at both sites |
| Route of administration | Subcutaneous injection | No approved oral form at present |
| Elimination half-life | About 5 days | Supports extended intervals between administrations |
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
-values are taken from AME2020, while the electron binding energies are taken from NIST. See (Ran & Wang, 2026) for more details. Please note that the ionization energies for highly-ionized atoms are theoretical.
In some instances 189F can combine with a helium nucleus, forming 2111Na, to start a neon-sodium cycle, in which: 2111Na → 2110Ne → 2211Na → 2210Ne → 2311Na → 2010Ne → 2111Na The sodium-23 can also turn into magnesium-24 after proton bombardment, initiating a magnesium-aluminium cycle, in which: 2412Mg → 2513Al → 2512Mg → 2613Al → 2612Mg → 2713Al → 2412Mg
Leumorphin, also known as dynorphin B1–29, is a naturally occurring endogenous opioid peptide. Derived as a proteolytic cleavage product of residues 226-254 of prodynorphin (preproenkephalin B), leumorphin is a nonacosapeptide (29 amino acids in length) and has the sequence Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr-Arg-Ser-Gln-Glu-Asp-Pro-Asn-Ala-Tyr-Ser-Gly-Glu-Leu-Phe-Asp-Ala. It can be further reduced to dynorphin B (dynorphin B-13) and dynorphin B-14 by pitrilysin metallopeptidase 1 (formerly referred to as "dynorphin-converting enzyme"), an enzyme of the endopeptidase family. Leumorphin behaves as a potent and selective κ-opioid receptor agonist, similarly to other endogenous opioid peptide derivatives of prodynorphin.
Sources: en.wikipedia.org
== Chemical Modifications == The general purpose of HA modifications is to improve certain properties such as biocompatibility, permeation, and sustained drug release. It can also be modified to test the functionality of certain groups, such as the carboxyl or hydroxyl groups. These improvements to HA are achieved through cross-linking and bioconjugation with various molecules, such as acid derivatives, ketones, aldehydes, biopolymers, and probes. There are three sites on HA that can be modified: the Carboxylic acid group (COOH), the hydroxyl group (OH), and the N-acetyl group (NHCOH3). Modifications of the carboxylic acid group include amidation, Ugi condensation, and ester formation. Modifications of the hydroxyl group include ether formation, hemiacetal formation, ester formation, carbamate formation, and oxidation with sodium periodate. Modifications of the N-acetyl group include deacetylation, followed by amidation or Ugi condensation.
== Sources == U7-CNTX-Pn1a is naturally found in the venom of Phoneutria nigriventer, often referred to as the Brazilian wandering or 'armed' spider. Additionally, the recombinant protein has been produced based on the amino acid sequence derived from the isolated neurotoxin.
Jonathan Lavine (1988), business executive, co-managing partner of Bain Capital and chief investment officer of Bain Capital Credit Anita Lo (1988), celebrity chef and restaurateur Danielle Maged (1989), Fox Networks Group executive Joanne Ooi (1989), former creative director of Shanghai Tang; CEO of Clean Air Network and Plukka Paul Greenberg (1990), former CEO of CollegeHumor and current CEO of Nylon Prem Parameswaran (1990), CFO of Eros International Plc and member of the President's Advisory Commission on Asian Americans and Pacific Islanders William von Mueffling (1990), hedge fund manager, president of Cantillon Capital Management Christoph Westphal (1990), biomedical entrepreneur, founder of Alnylam Pharmaceuticals, Acceleron Pharma, and OvaScience Marko Ahtisaari (1991), Finnish entrepreneur; founding CEO of Dopplr; son of Martti Ahtisaari, tenth President of Finland and Nobel Peace Prize laureate Claude Arpels (1991), investor, entrepreneur, grandson of Julien Arpels and heir to the Van Cleef & Arpels fortune Tewodros Ashenafi (1991), founder and CEO of Ethiopian company SouthWest Energy Jack Hidary (1991), financier and entrepreneur, co-founder of the Automotive X Prize and EarthWeb/Dice Inc. E. Javier Loya (1991), CEO of OTC Global Holdings and minority owner in Houston Texans Zia Chishti (1992), entrepreneur and founder of Afiniti and Align Technology Erik Feig (1992), Lionsgate co-president and former president of Summit Entertainment; producer of Step Up series, Escape Plan, Mr. & Mrs.
== White Book == The White Book, formally titled Biochemical Nomenclature and Related Documents (1992), contains definitions pertaining to biochemical research, compiled jointly by IUPAC and the International Union of Biochemistry and Molecular Biology.
Sources: en.wikipedia.org
== Awards and honors == Sheiner received the Oscar B. Hunter Award, the highest honor of the American Society for Clinical Pharmacology and Therapeutics (ASCPT), in 2004. He was given an Honorary Doctorate from Uppsala University, Sweden in 1995 and received the Rawls Palmer Progress in Medicine Award of the ASCPT in 1989. Posthumously, several awards have been named in Sheiner's honor, including the International Society of Pharmacometrics (ISoP) Lewis B. Sheiner Lecturer Award and the ASCPT's Sheiner-Beal Pharmacometrics Award.
Amikacin Amoxicillin/clavulanic acid (amoxicillin + clavulanic acid) Bedaquiline Clofazimine Cycloserine Delamanid Ethambutol Ethambutol/isoniazid/pyrazinamide/rifampicin (ethambutol + isoniazid + pyrazinamide + rifampicin) Ethambutol/isoniazid/rifampicin (ethambutol + isoniazid + rifampicin) Ethionamide Isoniazid Isoniazid/pyrazinamide/rifampicin (isoniazid + pyrazinamide + rifampicin) Isoniazid/rifampicin (isoniazid + rifampicin) Isoniazid/rifapentine (isoniazid + rifapentine) Levofloxacin Linezolid Meropenem Moxifloxacin P-aminosalicylic acid (p-aminosalicylate sodium) Pretomanid Pyrazinamide Rifabutin Rifampicin Rifapentine Streptomycin
daltons. HDC differs from other types of chromatography because the separation only takes place in the interstitial volume, which is the volume surrounding and in between particles in a packed column. HDC shares the same order of elution as Size Exclusion Chromatography (SEC) but the two processes still vary in many ways. In a study comparing the two types of separation, Isenberg, Brewer, Côté, and Striegel use both methods for polysaccharide characterization and conclude that HDC coupled with multiangle light scattering (MALS) achieves more accurate molar mass distribution when compared to off-line MALS than SEC in significantly less time. This is largely due to SEC being a more destructive technique because of the pores in the column degrading the analyte during separation, which tends to impact the mass distribution. However, the main disadvantage of HDC is low resolution of analyte peaks, which makes SEC a more viable option when used with chemicals that are not easily degradable and where rapid elution is not important.
Sources: en.wikipedia.org
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.
Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.
The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.
Liquid chromatography combined with mass spectrometry is the most common approach. Digestion followed by peptide mapping verifies the sequence and modification sites. Results are judged against a reference standard or a theoretically calculated mass.